HOME >> BIOLOGY >> NEWS
Data show investigational antibiotic safe, effective in preventing travelers diarrhea

New Orleans, LA — New data suggest the investigational drug rifaximin, a non-absorbed (less than .5%) antibiotic with few side effects and low potential for resistance, is effective in preventing travelers' diarrhea, an illness that affects up to 60 percent of international travelers. Until now, antimicrobial prophylaxis, while effective, has been discouraged because of side effects and the encouragement of resistance. The study results, presented Sunday, May 16 at the 2004 Digestive Disease Week (DDW) annual meeting by lead investigator, Herbert L. DuPont, M.D., Chief of the Internal Medicine Service at St. Luke's Episcopal Hospital in Houston, showed that, over two weeks, 85 percent of the rifaximin-treated subjects remained free of diarrhea, compared with 49 percent of the placebo-treated subjects.

Dr. DuPont is also Director, Center for Infectious Diseases, University of Texas, Houston School of Public Health and Vice-Chairman, Department of Medicine at Baylor College of Medicine.

Travelers' diarrhea threatens up to 50 million persons going to Mexico and Latin America, Africa and southern Asia each year. The illness can render travelers bed ridden for a full day or more, and considerably decrease their energy for up to a week or longer. In addition, a bout of travelers' diarrhea can also cause chronic diarrhea and long-lasting irritable bowel syndrome in some people. The antibiotic, rifaximin, with the projected brand name of Xifaxan, is currently under review by the U.S. Food and Drug Administration. It has previously been shown by researchers to be a safe and effective form of therapy for treatment of travelers' diarrhea in clinical studies conducted in Mexico, Peru, India and Kenya and has been prescribed internationally since 1987 and is currently approved in 17 countries worldwide.

"This is potentially one of the most important advances over the past 50 years toward reducing the occurrence of illness of travelers to
'"/>


16-May-2004


Page: 1 2 3

Related biology news :

1. Hemophilia therapy update: New information on investigational Factor VIII therapy development
2. New research on investigational Alzheimers disease treatment suggests significant improvement of symptoms
3. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
4. Smart antibiotics may result from UCLA research
5. K-State researcher working to improve alternatives to equine antibiotics
6. Bacterial protein recycling factor possible key to new class of antibiotics
7. Bacteria spill their guts to aid researchers in quest for new antibiotics
8. Molecule that blocks key bacterial enzyme may lead to new antibiotics
9. Does antibiotic use contribute to allergies?
10. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
11. Tigecycline - antibiotic evaluated in surveillance trial

Post Your Comments:
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that four of its ... solution, have officially been named FIDO Certified™ by ... of the certification, Synaptics, Natural ID™ fingerprint solutions ... Authentication Framework (UAF) standard and are interoperable among ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
(Date:9/4/2015)... ... September 04, 2015 , ... ... bioprinter, the BioBot 1, at the 2015 TERMIS World Congress in Boston. The ... and biomedical engineering institutions around the world. The printer is revolutionary for its ...
(Date:9/3/2015)... Sept. 3, 2015  Guardant Health®, the leader ... highlighting the performance and clinical utility of Guardant360® ... oral and poster presentations at the International Association ... Conference on Lung Cancer. These abstracts were submitted ... California, Davis; the University of Chicago; Sarah Cannon ...
(Date:9/3/2015)... India , September 3, 2015 ... Instruments Market by System (LC (HPLC, UHPLC, Flash), GC, ... Phase Columns, Syringe Filters, Vials) - Analysis & Global ... Market is expected to reach around 9.223 Billion by ... CAGR of 5.5%. Browse 141 tables and ...
(Date:9/2/2015)... Bermuda , Sept. 2, 2015 Axovant Sciences ... the treatment of dementia, today announced upcoming presentations at three ... PM at the Baird 2015 Healthcare Conference in ... , Thursday, September 10 at 2:00 PM at the ... at the Millennium Broadway Hotel & Conference Center , ...
Breaking Biology Technology:BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 2BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 3BioBots to Debut Desktop 3D Bioprinter for Living Tissue at TERMIS Global Tissue Engineering Conference in Boston 4Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 2Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 3Leading Cancer Centers to Present Clinical Utility Data For Guardant360 At IASLC's 16th World Conference on Lung Cancer in Denver Sept. 6-9 4Chromatography Instruments Market Worth $ 9.223 Billion by 2020 2Chromatography Instruments Market Worth $ 9.223 Billion by 2020 3Chromatography Instruments Market Worth $ 9.223 Billion by 2020 4Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3
Cached News: